HORSHAM, Pa.–(BUSINESS WIRE)–Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney,…
Financing round led by Samsara BioCapital to advance Phase 3 ALERT Study. HORSHAM, Pa. – September 25, 2020 Palladio Biosciences,…
NEWTOWN, Pa. — Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the…
NEWTOWN, Pa.–(BUSINESS WIRE)–Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/, a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney,…
NEWTOWN, Pa. — Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the…
–Addition of Experienced Executive to Leadership Team– Newtown, PA: April 3, 2019. Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/, a private biopharmaceutical…
–Dr. Shusterman named as Palladio Biosciences, Inc., Chief Medical Officer– January 03, 2019 09:20 AM Eastern Standard Time NEWTOWN, Pa.–(BUSINESS…
–ELiSA Study designed to evaluate the safety and activity of multiple doses of lixivaptan in patients with ADPKD– December 18,…
–Patient enrollment into the study expected to begin by the end of June 2018– NEWTOWN, Pa., May 8, 2018 –(BUSINESS…
Palladio Biosciences was featured in the Emerging Company Profile section of the March 8, 2018 edition of BioCentury. The full…